Eisenmenger Syndrome

How it works

Risks & contraindications

Evidence quality

Other

Highlighted claims

• Eisenmenger syndrome is described as the advanced end of pulmonary arterial hypertension associated with unrepaired congenital heart disease. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• Progressive pulmonary vascular remodelling can reverse shunt flow and cause cyanosis and multiorgan complications. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• Many adults with Eisenmenger syndrome or vasodilator-resistant unrepaired CHD-PAH are not candidates for defect closure. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri
• Evidence for existing pharmacotherapy in Eisenmenger syndrome is limited and mixed. — Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atri